New Fat-Targeting Injection Shows Promise for Flatter Stomach and Reduced Visceral Fat

A new generation of weight loss injection, known as CBL-514, has shown potential in helping overweight adults achieve a flatter stomach and reduce dangerous visceral fat, according to research presented by US scientists. The drug works by directly targeting and triggering the self-destruction of fat cells, a mechanism distinct from current weight loss injections that primarily mimic the hormone GLP-1 to induce feelings of fullness.

In a Phase 2 clinical trial involving 41 participants, approximately 70% of those treated with CBL-514 experienced a reduction of at least 150ml of visible subcutaneous fat over an eight-week period. After one month of the final treatment, patients receiving CBL-514 showed a 12% decrease in visceral fat compared to the start of the study, while the placebo group saw a nearly 6% increase. By two months post-treatment, the drug group had approximately 10% less visceral fat, whereas the placebo group experienced an 11.8% increase.

Visceral fat, which surrounds internal organs, is associated with an increased risk of heart attack, diabetes, and stroke. The study indicated that CBL-514 could offer a less invasive alternative to cosmetic procedures like liposuction for reducing stubborn fat deposits.

Furthermore, preliminary findings suggest that using CBL-514 in conjunction with tirzepatide (Mounjaro) may enhance weight loss effects and potentially mitigate weight regain after discontinuing treatment. In animal studies, rats treated with both CBL-514 and tirzepatide lost more weight and regained less when tirzepatide was stopped, though the exact mechanism for this sustained effect is still under investigation. Current weight loss injections like Wegovy and Mounjaro, while effective, are often associated with significant weight regain within two years of cessation.

Dr. Timothy Garvey, an expert in metabolic diseases at the University of Alabama and a lead researcher on the study, expressed optimism about the cosmetic benefits, such as a flatter stomach from subcutaneous fat loss. However, he emphasized that the reduction in body weight, visceral fat, and associated improvements in blood pressure and cholesterol levels are more significant for overall health. CBL-514 was generally well-tolerated, with reported side effects limited to redness and pain at the injection site.

While the results are described as encouraging by independent experts, larger Phase 3 trials are planned to further evaluate the drug's safety and efficacy for belly fat reduction and to confirm the longevity of the fat reduction and its impact on health outcomes. Researchers also noted that the drug was initially developed to target localized fatty lumps under the skin, but its potential application in treating cardiometabolic diseases is significant, provided it does not increase fat accumulation in other organs.

These findings emerge alongside research on other combination therapies, such as EloraTZP, which combines tirzepatide with eloralintide and has shown substantial weight loss percentages. The ongoing development of drugs like CBL-514 signals a continued advancement in pharmacologic approaches to weight management and the treatment of obesity-related health conditions.